Your browser doesn't support javascript.
loading
Subcutaneous Implantable Cardioverter Defibrillator: Early Experience.
Souza, Fernando Sérgio Oliva; Matos, Vanessa Sepulvida; Almeida, Marcos Cesar Valério; Weiss, Samuel Campagiotto; Rodrigues, Lucas Henrique Borges; Lima, Pedro Augusto Gori; Mattos, Davi Bongiolo.
Afiliação
  • Souza FSO; Instituto de Arritmias Cardíacas (IAC), São Paulo, SP, Brazil.
  • Matos VS; Hospital Beneficência Portuguesa São Paulo, São Paulo, SP, Brazil.
  • Almeida MCV; Instituto de Arritmias Cardíacas (IAC), São Paulo, SP, Brazil.
  • Weiss SC; Hospital Beneficência Portuguesa São Paulo, São Paulo, SP, Brazil.
  • Rodrigues LHB; Hospital Beneficência Portuguesa São Paulo, São Paulo, SP, Brazil.
  • Lima PAG; Instituto de Arritmias Cardíacas (IAC), São Paulo, SP, Brazil.
  • Mattos DB; Hospital Beneficência Portuguesa São Paulo, São Paulo, SP, Brazil.
Braz J Cardiovasc Surg ; 32(6): 498-502, 2017.
Article em En | MEDLINE | ID: mdl-29267613
INTRODUCTION: The implantable cardioverter defibrillator had been increasing the survival of patients at high risk for sudden cardiac death. The subcutaneous implantable cardioverter defibrillator was developed to mitigate the complications inherent to lead placement into cardiovascular system. OBJECTIVE: To report the initial experience of 18 consecutive cases of subcutaneous implantable cardioverter defibrillator implantation showing the indications, potential pitfalls and perioperative complications. METHODS: Between September 2016 and March 2017, 18 patients with indication for primary and secondary prevention of sudden cardiac death, with no concomitant indication for artificial cardiac pacing, were included. RESULTS: The implantation of the subcutaneous implantable cardioverter defibrillator successfully performed in 18 patients. It was difficult to place the subcutaneous lead at the parasternal line in two patients. One patient returned a week after the procedure complaining about an increase in pain intensity at pulse generator pocket site, which was associated with edema, temperature rising and hyperemia. Two patients took antialgic medication for five days after surgery. A reintervention was necessary in one patient to replace the lead in order to correct inappropriate shocks caused by myopotential oversensing. CONCLUSION: In our initial experience, although the subcutaneous implantable cardioverter defibrillator implantation is a less-invasive, simple-accomplishment procedure, it resulted in a bloodier surgery perhaps requiring an operative care different from the conventional. Inappropriate shock by oversensing is a reality in this system, which should be overcame in order not to become a limiting issue for its indication.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Ventricular / Cardioversão Elétrica / Estimulação Cardíaca Artificial / Morte Súbita Cardíaca / Desfibriladores Implantáveis / Prevenção Secundária Tipo de estudo: Etiology_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Braz J Cardiovasc Surg Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Ventricular / Cardioversão Elétrica / Estimulação Cardíaca Artificial / Morte Súbita Cardíaca / Desfibriladores Implantáveis / Prevenção Secundária Tipo de estudo: Etiology_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Braz J Cardiovasc Surg Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil